NASDAQ: AMGN
Amgen Inc Stock

AMGN Price
$224.89
Fair Value Price
N/A
Market Cap
$132.29B
52 Week Low
$182.24
52 Week High
$260.95
P/E
18.24x
P/B
12.41x
P/S
5.71x
PEG
1.38x
Dividend Yield
2.71%
Revenue
$24.30B
Earnings
$7.30B
Gross Profit Margin
78.2%
Operating Margin
39.36%
Net Profit Margin
30%
Debt to Equity
5.1
Operating Cash Flow
$11B
Beta
0.88
Next Earnings
Oct 28, 2020
Ex-Dividend
Nov 13, 2020
Next Dividend
Dec 8, 2020

AMGN Overview

Zen Score

High
Medium
Low
49
Industry average

Reasons for this score

AMGN ($224.89) is trading below its intrinsic value of $740.01, according to Benjamin Graham's Formula from Chapter 14 of "The Intelligent Investor"
Valuation
AMGN is good value based on its earnings relative to its share price (18.24x), compared to the US market average 42.6x)
Valuation
AMGN is good value based on its earnings relative to its share price (18.24x), compared to the US Drug Manufacturers - General industry average (-10.13x)
Valuation

1 of 13

AMGN News

Valuation

AMGN price to earnings (PE)

For valuing profitable companies with steady earnings
Company
18.24x
Industry
-10.13x
Market
42.6x
AMGN is good value based on its earnings relative to its share price (18.24x), compared to the US market average 42.6x)
Valuation
AMGN is good value based on its earnings relative to its share price (18.24x), compared to the US Drug Manufacturers - General industry average (-10.13x)
Valuation

AMGN price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
12.41x
Industry
7.86x
Market
62.61x
AMGN is good value based on its book value relative to its share price (12.41x), compared to the US market average (62.61x)
Valuation
AMGN is poor value based on its book value relative to its share price (12.41x), compared to the US Drug Manufacturers - General industry average (7.86x)
Valuation

AMGN price to earnings growth (PEG)

For valuing profitable companies with growth potential
AMGN is poor value relative to its rate of earnings growth, measured by PEG ratio (1.38x)
Valuation

AMGN's financial health

Profit margin

Revenue
$6.2B
Net Income
$1.8B
Profit Margin
29.6%
AMGN's Earnings (EBIT) of $9.57B can safely cover interest payments on company debt ($34.22B)
Financials
AMGN's profit margin has decreased (-3.8%) in the last year from (33.8%) to (30%)
Financials

Assets to liabilities

Assets
$61.7B
Liabilities
$52.2B
Debt to equity
3.36
AMGN's short-term assets ($22.90B) exceed its short-term liabilities ($10.52B)
Financials
AMGN's long-term liabilities ($43.83B) exceed its short-term assets ($22.90B)
Financials
AMGN's debt has increased relative to shareholder equity (5.1), over the past 5 years ago (1.59)
Financials
AMGN's debt to equity ratio (5.1) is considered high
Financials

Cash flow

Operating
$2.1B
Investing
-$230.0M
Financing
-$254.0M
AMGN's operating cash flow ($10.87B) is sufficient to service the company's debt ($34.22B)
Financials

Amgen Stock FAQ

(NASDAQ: AMGN) Amgen trades on the NASDAQ under the ticker symbol AMGN. Amgen stock quotes can also be displayed as NASDAQ: AMGN.
(NASDAQ: AMGN) Amgen stock price per share is $224.89 today (as of Oct 26, 2020).
(NASDAQ: AMGN) Amgen's 52-week high was $260.95, and its 52-week low was $182.24. It is currently -13.82% from its 52-week high and 23.4% from its 52-week low.
(NASDAQ: AMGN) Amgen's market cap is $132.29B, as of Oct 27, 2020.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Amgen's market cap is calculated by multiplying AMGN's current stock price of $224.89 by AMGN's total outstanding shares of 588247399.
(NASDAQ: AMGN) Amgen currently has 588247399 outstanding shares. With Amgen stock trading at $224.89 per share, the total value of Amgen stock (market capitalization) is $132.29B.

Amgen stock was originally listed at a price of $13.53 in Dec 31, 1997. If you had invested in Amgen stock at $13.53, your return over the last 22 years would have been 1561.79%, for an annualized return of 13.63%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Heap | Mobile and Web Analytics